HOUSTON, March 11, 2020 /PRNewswire-PRWeb/ -- Greffex, Inc., a leading genetic engineering company, revealed its completion of a Covid-19 vaccine and is ready to move on to animal testing as required by the U.S. government Food and Drug Administration.
"This is a major development for the entire world population," said Greffex CEO, John Price. "Greffex's ability to scale the vaccine appropriately, test quickly and efficiently and fast track it to patients, gives us an edge over other research facilities and we're looking forward to the next step of animal testing."
Greffex did not use a living or killed virus for its vaccine and instead used an adenovirus-based vector vaccine, which are genetically engineered.
Once the vaccine is approved by the government, Greffex has committed free distribution of the vaccine to other countries for free.
In 2019, Greffex was awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This award will enable GREFFEX to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or man-made.
About Greffex Founded in 2005 to pursue disruptive and proprietary technology that its founders had first explored in 1998, GREFFEX has created the most versatile gene delivery vehicle with broad applications in vaccination, gene therapy and tissue engineering and, in process, has become a leading Genetic Engineering Company. The company has 14 vaccines in its development portfolio, numerous gene therapies in development including Hemophilia A and Usher Syndrome, and immune tissue engineering aimed at overcoming transplant rejection. GREFFEX is headquartered in Houston, Texas and its laboratories are located in Aurora, Colorado.
SOURCE Greffex
Advertisement
"This is a major development for the entire world population," said Greffex CEO, John Price. "Greffex's ability to scale the vaccine appropriately, test quickly and efficiently and fast track it to patients, gives us an edge over other research facilities and we're looking forward to the next step of animal testing."
Advertisement
Greffex did not use a living or killed virus for its vaccine and instead used an adenovirus-based vector vaccine, which are genetically engineered.
Once the vaccine is approved by the government, Greffex has committed free distribution of the vaccine to other countries for free.
In 2019, Greffex was awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This award will enable GREFFEX to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or man-made.
About Greffex Founded in 2005 to pursue disruptive and proprietary technology that its founders had first explored in 1998, GREFFEX has created the most versatile gene delivery vehicle with broad applications in vaccination, gene therapy and tissue engineering and, in process, has become a leading Genetic Engineering Company. The company has 14 vaccines in its development portfolio, numerous gene therapies in development including Hemophilia A and Usher Syndrome, and immune tissue engineering aimed at overcoming transplant rejection. GREFFEX is headquartered in Houston, Texas and its laboratories are located in Aurora, Colorado.
SOURCE Greffex
